Cystinosis pipeline progresses, 2024 market hits $250m

DelveInsight says the cystinosis treatment market across major markets totaled about $250 million in 2024, with the USA accounting for roughly 84% of sales. The research group also estimates 1,540 diagnosed prevalent cases across those markets in 2024, underscoring how concentrated care remains in specialist metabolic and nephrology centers.

In its latest market report, DelveInsight argues that the treatment landscape is still anchored to cysteamine-based standards of care, despite clear trade-offs in tolerability and convenience. It points to Procysbi and Cystagon/Nicystagon (cysteamine bitartrate) for systemic disease control, and Cystadrops (cysteamine) plus Cystaran (cysteamine) for ocular use, saying dosing burden and adherence challenges continue to limit long-term disease control and quality of life.

On the pipeline front, DelveInsight highlights Thiogenesis Therapeutics’ (CVE: TTI) TTI-0102 and Novartis’ (NOVN: VX) DFT383 as notable programs that could shift the field toward more durable cystine control and, potentially, disease modification. The report frames the next few years as a test of whether these approaches can move cystinosis beyond incremental tweaks to cysteamine delivery.